Ethosuximide Oral Solution USP 250 mg/5 mL — Class II drug recall D-0723-2021
Terminated recall by PAI Holdings, LLC. dba Pharmaceutical Associates Inc, reported 2021-08-18, distributed nationwide. Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
| Recall number | D-0723-2021 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | PAI Holdings, LLC. dba Pharmaceutical Associates Inc, Greenville, SC, United States |
| Recall initiated | 2021-07-29 |
| Classified | 2021-08-12 |
| Reported by FDA | 2021-08-18 |
| Terminated | 2022-12-02 |
| Distributed | Nationwide (US) |
| Reason classes | cgmp |
| NDC | 00121-0670, 00121-0670-16 |
| Lot numbers | C9BC |
| Expiration dates | 2022-10-31 |
Product
Ethosuximide Oral Solution USP 250 mg/5 mL, 16 fl oz (473 mL), Rx ONLY, Pharmaceutical Associates, Inc. Greenville, SC 29605, NDC 0121-0670-16
Reason for recall
Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0723-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.